Using translational research to tailor the use of chemotherapy in the treatment of NSCLC
Using translational research to tailor the use of chemotherapy in the treatment of NSCLC
复制标题
DOI：
10.1016/s0169-5002(05)81553-3
复制
发表时间：
2005-10-01
期刊：
影响因子：
5.3
通讯作者：
Bepler, G
中科院分区：
文献类型：
--
作者：
Bepler, G
随着吉西他滨、紫杉烷和长春瑞滨等新药物的问世，晚期非小细胞肺癌(NSCLC)的治疗在过去20年中得到了改善。尽管取得了这些进展，但对大多数患者来说，生存前景仍然令人失望。进一步提高应答率和存活率需要开发具有新作用机制的新药物，例如目前正在进行临床试验的分子靶向疗法。NSCLC的传统治疗方法正开始转向应用特定的策略和技术，如药物基因组学，以针对个别患者进行量身定制的治疗。许多努力正在进行中，以确定影响结果的临床预测因素。预后分子标志物的发现，如假定的抑制基因(RRM1)，代表了一个新的和潜在的参数，以帮助指导临床治疗决策。(C)2005爱思唯尔爱尔兰有限公司。保留所有权利。
The treatment of advanced non-small-cell lung cancer (NSCLC) has improved over the past two decades with the availability of new agents such as gemcitabine, the taxanes and vinorelbine. Despite these advances, survival prospects remain disappointingly tow for most patients. Further improvements in response rate and survival requires the development of new agents with novel mechanisms of action, such as molecularly targeted therapies, which are currently being tested in clinical trials. The conventional treatment approach to NSCLC is beginning to shift towards the application of specific strategies and techniques, such as pharmacogenomics, to tailor treatment to individual patients. Many efforts are in progress to identify the clinical predictors of outcome. The discovery of prognostic molecular markers, such as the putative suppressor gene (RRM1), represents a novel and potential parameter to help guide clinical treatment decisions. (c) 2005 Elsevier Ireland Ltd. All rights reserved.